NCT06688968 Neuropsychological Profiles and Musical Engagement in Parkinson's and Alzheimer's Disease
| NCT ID | NCT06688968 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Montpellier |
| Condition | Alzheimer Disease, Early Onset |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2025-02-04 |
| Primary Completion | 2025-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 120 participants in total. It began in 2025-02-04 with a primary completion date of 2025-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this Multicenter observational pilot study is to Compare the specifics of musical engagement (behaviors related to music in everyday life) in subjects aged over 60 with Alzheimer s disease, Parkinson s disease and control subjects. The main questions it aims to answer are: 1. The description of different profiles of musical engagement in early-stage AD, in PD and in healthy elderly subjects. 2. The extent of executive, mnestic and hedonic dysfunctions will impact differently on emotional engagement, autobiographical evocation and sensitivity to musical reward, and will therefore enable distinct profiles to be drawn up. Participants will have an intervention consisting of an interview with a neuropsychologist lasting approximately 2 hours, including : * A semi-structured interview to check the participants eligibility and gather demographic data. * Neuropsychological tests and questionnaires will then be administered. * A relative of the study participant will help complete questionnaires.
Eligibility Criteria
Inclusion Criteria: General inclusion criteria: * 60 years and older * French-speaking and volunteering for the study * Living at home with a relative Alzheimer's disease inclusion criteria: * Biological diagnosis of probable Alzheimer's disease according to NINCDS-ADRDA criteria (McKhann et al., 1984) * MMSE greater than or equal to 20 Inclusion criteria Parkinson's disease : * Diagnosis of Idiopathic Parkinson's disease * MMSE greater than or equal to 20 Exclusion Criteria: * No known neurological pathologies (epilepsy and other non-degenerative CNS diseases) or psychiatric disorders (chronic psychosis and psychotic episodes) * Autistic disorders * History of stroke or head trauma * Unstable medical condition (cancer) * Subject unable to read and/or write * Hearing impairment without hearing aids * Refusal of consent after information * Persons unable to give consent, research carried out in emergency situations, etc.) * Non-affiliation with a social security scheme * Person deprived of liberty (by judicial or administrative decision, or forced hospitalization) * Person under legal protection (guardianship, curatorship, legal protection) * Person participating in another research project with an exclusion period still in progress
Contact & Investigator
KARIM BENNYS, MD
PRINCIPAL INVESTIGATOR
University Hospital, Montpellier
Frequently Asked Questions
Who can join the NCT06688968 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, studying Alzheimer Disease, Early Onset. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06688968 currently recruiting?
Yes, NCT06688968 is actively recruiting participants. Contact the research team at mikael.genguelou@univ-montp3.fr for enrollment information.
Where is the NCT06688968 trial being conducted?
This trial is being conducted at Montpellier, France, Montpellier, France, Montpellier, France.
Who is sponsoring the NCT06688968 clinical trial?
NCT06688968 is sponsored by University Hospital, Montpellier. The principal investigator is KARIM BENNYS, MD at University Hospital, Montpellier. The trial plans to enroll 120 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.